Agilon Health, Inc. (NYSE:AGL - Get Free Report)'s share price traded up 4.4% during mid-day trading on Friday. The stock traded as high as $78.24 and last traded at $79.1680. Approximately 15,002 shares traded hands during mid-day trading, a decline of 96% from the average daily volume of 335,667 shares. The stock had previously closed at $75.83.
Analyst Ratings Changes
AGL has been the topic of a number of recent research reports. Sanford C. Bernstein upgraded Agilon Health from a "market perform" rating to an "outperform" rating and lifted their target price for the stock from $86.00 to $125.00 in a report on Tuesday, September 15th. Citigroup upgraded Agilon Health from a "sell" rating to a "neutral" rating and increased their price target for the company from $105.00 to $115.00 in a research report on Monday, August 10th. Robert W. Baird set a $116.00 price target on Agilon Health in a research note on Thursday, August 6th. Benchmark restated a "buy" rating and set a $140.00 price objective (up from $95.00) on shares of Agilon Health in a report on Thursday, August 6th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Agilon Health from $31.00 to $85.00 and gave the company an "underweight" rating in a research note on Monday, August 24th. Six investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $102.25.
View Our Latest Stock Analysis on Agilon Health
Agilon Health Stock Performance
The firm has a 50 day moving average of $94.72 and a 200-day moving average of $74.10. The stock has a market capitalization of $1.41 billion, a PE ratio of -5.86 and a beta of 3.02. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.08 and a current ratio of 1.08.
Agilon Health (NYSE:AGL - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.90. The company had revenue of $1.49 billion for the quarter, compared to analysts' expectations of $1.45 billion. Agilon Health had a negative return on equity of 119.38% and a negative net margin of 3.92%. Research analysts forecast that Agilon Health, Inc. will post -2.9 earnings per share for the current year.
Institutional Trading of Agilon Health
Several hedge funds and other institutional investors have recently modified their holdings of AGL. Rubicon Founders LLC bought a new stake in shares of Agilon Health in the 2nd quarter valued at approximately $11,290,448. Tidal Investments LLC acquired a new stake in Agilon Health in the second quarter valued at approximately $1,405,000. State Street Corp acquired a new stake in Agilon Health in the second quarter valued at approximately $30,024,000. Great Lakes Advisors LLC bought a new stake in Agilon Health in the second quarter worth approximately $702,000. Finally, Alpine Global Management LLC bought a new stake in Agilon Health in the fourth quarter worth approximately $84,000.
About Agilon Health
(
Get Free Report)
Agilon Health, Inc is a healthcare company that partners with independent primary care physicians to support the transition from fee-for-service medicine to value-based care. The company focuses primarily on patients enrolled in Medicare Advantage plans and works with physician groups to coordinate care, improve outcomes and manage healthcare costs.
Agilon provides physicians with technology, analytics, operational support and clinical resources designed to help them manage the health of defined patient populations.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Agilon Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilon Health wasn't on the list.
While Agilon Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.